Cargando…
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
CD38 is a transmembrane glycoprotein with ectoenzymatic activity involved in regulation of migration, signal transduction, and receptor-mediated adhesion. CD38 is highly expressed on various malignant cells, including multiple myeloma (MM), and at relatively low levels in other tissues, making it a...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953105/ https://www.ncbi.nlm.nih.gov/pubmed/31779273 http://dx.doi.org/10.3390/cells8121522 |
_version_ | 1783486574906834944 |
---|---|
author | Martin, Thomas G. Corzo, Kathryn Chiron, Marielle van de Velde, Helgi Abbadessa, Giovanni Campana, Frank Solanki, Malini Meng, Robin Lee, Helen Wiederschain, Dmitri Zhu, Chen Rak, Alexey Anderson, Kenneth C. |
author_facet | Martin, Thomas G. Corzo, Kathryn Chiron, Marielle van de Velde, Helgi Abbadessa, Giovanni Campana, Frank Solanki, Malini Meng, Robin Lee, Helen Wiederschain, Dmitri Zhu, Chen Rak, Alexey Anderson, Kenneth C. |
author_sort | Martin, Thomas G. |
collection | PubMed |
description | CD38 is a transmembrane glycoprotein with ectoenzymatic activity involved in regulation of migration, signal transduction, and receptor-mediated adhesion. CD38 is highly expressed on various malignant cells, including multiple myeloma (MM), and at relatively low levels in other tissues, making it a suitable target for therapeutic antibodies. Several anti-CD38 therapies have been, or are being, developed for the treatment of MM, including daratumumab and isatuximab (SAR650984), respectively. Studies have shown that anti-CD38 therapies are effective in the treatment of relapsed/refractory MM and are well tolerated, with infusion reactions being the most common side effects. They can be used as monotherapy or in combination with immunomodulatory agents, such as pomalidomide, or proteasome inhibitors to potentiate their activity. Here we examine isatuximab and several anti-CD38 agents in development that were generated using new antibody engineering techniques and that may lead to more effective CD38 targeting. We also summarize trials assessing these antibodies in MM, other malignancies, and solid organ transplantation. Finally, we propose that further research on the mechanisms of resistance to anti-CD38 therapy and the development of biomarkers and new backbone regimens with CD38 antibodies will be important steps in building more personalized treatment for patients with MM. |
format | Online Article Text |
id | pubmed-6953105 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69531052020-01-23 Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab Martin, Thomas G. Corzo, Kathryn Chiron, Marielle van de Velde, Helgi Abbadessa, Giovanni Campana, Frank Solanki, Malini Meng, Robin Lee, Helen Wiederschain, Dmitri Zhu, Chen Rak, Alexey Anderson, Kenneth C. Cells Review CD38 is a transmembrane glycoprotein with ectoenzymatic activity involved in regulation of migration, signal transduction, and receptor-mediated adhesion. CD38 is highly expressed on various malignant cells, including multiple myeloma (MM), and at relatively low levels in other tissues, making it a suitable target for therapeutic antibodies. Several anti-CD38 therapies have been, or are being, developed for the treatment of MM, including daratumumab and isatuximab (SAR650984), respectively. Studies have shown that anti-CD38 therapies are effective in the treatment of relapsed/refractory MM and are well tolerated, with infusion reactions being the most common side effects. They can be used as monotherapy or in combination with immunomodulatory agents, such as pomalidomide, or proteasome inhibitors to potentiate their activity. Here we examine isatuximab and several anti-CD38 agents in development that were generated using new antibody engineering techniques and that may lead to more effective CD38 targeting. We also summarize trials assessing these antibodies in MM, other malignancies, and solid organ transplantation. Finally, we propose that further research on the mechanisms of resistance to anti-CD38 therapy and the development of biomarkers and new backbone regimens with CD38 antibodies will be important steps in building more personalized treatment for patients with MM. MDPI 2019-11-26 /pmc/articles/PMC6953105/ /pubmed/31779273 http://dx.doi.org/10.3390/cells8121522 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Martin, Thomas G. Corzo, Kathryn Chiron, Marielle van de Velde, Helgi Abbadessa, Giovanni Campana, Frank Solanki, Malini Meng, Robin Lee, Helen Wiederschain, Dmitri Zhu, Chen Rak, Alexey Anderson, Kenneth C. Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab |
title | Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab |
title_full | Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab |
title_fullStr | Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab |
title_full_unstemmed | Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab |
title_short | Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab |
title_sort | therapeutic opportunities with pharmacological inhibition of cd38 with isatuximab |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953105/ https://www.ncbi.nlm.nih.gov/pubmed/31779273 http://dx.doi.org/10.3390/cells8121522 |
work_keys_str_mv | AT martinthomasg therapeuticopportunitieswithpharmacologicalinhibitionofcd38withisatuximab AT corzokathryn therapeuticopportunitieswithpharmacologicalinhibitionofcd38withisatuximab AT chironmarielle therapeuticopportunitieswithpharmacologicalinhibitionofcd38withisatuximab AT vandeveldehelgi therapeuticopportunitieswithpharmacologicalinhibitionofcd38withisatuximab AT abbadessagiovanni therapeuticopportunitieswithpharmacologicalinhibitionofcd38withisatuximab AT campanafrank therapeuticopportunitieswithpharmacologicalinhibitionofcd38withisatuximab AT solankimalini therapeuticopportunitieswithpharmacologicalinhibitionofcd38withisatuximab AT mengrobin therapeuticopportunitieswithpharmacologicalinhibitionofcd38withisatuximab AT leehelen therapeuticopportunitieswithpharmacologicalinhibitionofcd38withisatuximab AT wiederschaindmitri therapeuticopportunitieswithpharmacologicalinhibitionofcd38withisatuximab AT zhuchen therapeuticopportunitieswithpharmacologicalinhibitionofcd38withisatuximab AT rakalexey therapeuticopportunitieswithpharmacologicalinhibitionofcd38withisatuximab AT andersonkennethc therapeuticopportunitieswithpharmacologicalinhibitionofcd38withisatuximab |